Stockholders' Equity (Deficiency) (Details Narrative) - USD ($)						1 Months Ended		3 Months Ended			9 Months Ended			12 Months Ended
		May 31, 2017	Feb. 02, 2016	Feb. 02, 2016	Mar. 30, 2015	Dec. 31, 2017	Jul. 31, 2016	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2015
Common stock, shares authorized								125,000,000			125,000,000			125,000,000
Common stock, par value								$ 0.001			$ 0.001			$ 0.001
Preferred stock, shares authorized								10,000,000			10,000,000			10,000,000
Preferred stock, par value								$ 0.001			$ 0.001			$ 0.001
Common stock, shares issued								29,534,343			29,534,343			23,713,602
Common stock, shares outstanding								29,534,343			29,534,343			23,713,602
Exchangeable shares outstanding								4,868,464			4,868,464			8,143,937
Number of shares issued											211,666
Number of units sold											1,694,760
Proceeds from sale of units											$ 2,524,480
Stock issuance costs														$ 320,355
Proceeds from issuance of common stock											2,959,480	$ 4,860,970
Debt converted into shares, value											$ 2,436,406			$ 2,436,406
Number of shares issuable											14,000
Proceeds from exercise of warrants											$ 50,835	428,311
Number of shares issuable, value											$ (147,350)
Number of warrants exercised											62,838
Warrants exercise price per share								$ 0.7839			$ 0.7839
Expected life														3 years		10 years
Stock price														$ 0.60	$ 0.88	$ 0.74
Expected volatility														0.00%	0.00%	0.00%
Number of options granted														1,437,500
Stock based compensation											$ 1,100,686	646,970
Minimum [Member]
Expected life															1 year
Risk free rate														1.98%	0.45%	0.04%
Stock price								2.50			$ 2.50
Weighted average remaining contractual life														2 years 9 months 3 days
Maximum [Member]
Expected life															3 years
Risk free rate														2.81%	1.47%	1.07%
Stock price								2.70			$ 2.70
Weighted average remaining contractual life														9 years 6 months 3 days
2015 Equity Incentive Plan [Member]
Exchange ratio					1.1969:1
Number of shares issued for exercise of warrants											62,838
Number of shares issued for exercise of options											164,590		3,390,503				3,390,503
Number of options authorized to issue					3,000,000
Number of options vested											164,590
Number of options non-vested					137,500									164,590
Options exercise price					$ 0.0001			0.0001			$ 0.0001
Number of options cancelled														35,907
Fair value of options																	$ 2,257,953
Vesting description																	Options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favor of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.
Number of options granted													3,591,000
Number of options granted, exercise price											$ 0.0001		$ 0.0001
2016 Equity Incentive Plan [Member]
Number of shares issued for exercise of options
Number of options authorized to issue			3,750,000	3,750,000
Options exercise price								$ 3.1470	$ 3.2306		$ 3.1470			$ 3.2306
Fair value of options											$ 3,945,501	2,439,493
Plan description				The maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company's outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.
Number of options granted									4,147,498		257,500			4,147,498
Number of options granted, exercise price									$ 3.2306		$ 1.8000			$ 3.2306
Stock based compensation								$ 372,523		$ 204,815	$ 1,100,686	646,971
General and Administrative Expense [Member]
Number of shares issued											358,999
Number of shares issued, value											$ 875,879
Stock based compensation	[1],[2]							$ 316,544		$ 183,981	$ 1,060,712	$ 558,453
Accredited Investors [Member]
Number of units sold														1,282,767
Proceeds from sale of units														$ 2,244,845
Net proceeds from sale of units														$ 1,926,780
Accredited Investors [Member] | Private Placement [Member]
Number of units sold														263,188
Proceeds from sale of units														$ 460,579
Net proceeds from sale of units														413,629
Stock issuance costs														$ 46,950
Consultants [Member]
Number of shares issued														527,941
Number of shares issuable											18,750			20,250
Number of shares issued, value														$ 1,908,481
Number of shares issuable, value											$ 54,750
Number of shares issued for services											152,916
Number of shares issued for services, value											$ 73,400
Brokers [Member]
Number of shares issued														58,795
Cashless exercise of warrants														108,799
Investors [Member]
Number of shares issued											128,750
Stock issuance costs											$ 15,000
Proceeds from issuance of common stock											515,000
Aggregate purchase price of common stock											$ 25,000,000
Shares issued price per share								$ 4.00			$ 4.00
Investors One [Member]
Number of shares issued											121,344
Number of shares issued, value											$ 400,000
Advisors, Contractors and Consultants [Member]
Number of shares issued											372,999
Non-Executive Directors [Member]
Number of shares issued											62,500
Number of shares issued for services											40,000
Number of shares issued for services, value											$ 19,200
Non-Executive Directors [Member] | 2016 Equity Incentive Plan [Member]
Fair value of options											$ 31,959
Number of options granted											62,500
Number of options granted, exercise price											$ 2.00
Options vesting period											1 year
Advisor and Consultant [Member]
Number of warrants issued								508,333			508,333
Fair value of warrants											$ 376,136
Officer [Member] | 2016 Equity Incentive Plan [Member]
Number of options granted							2,499,998
Number of options granted, exercise price							$ 2.20
Options vesting period							3 years
Two Employees [Member] | 2016 Equity Incentive Plan [Member]
Number of options granted							175,000
Number of options granted, exercise price							$ 2.24
Options vesting period							1 year
One Employee [Member] | 2016 Equity Incentive Plan [Member]
Number of options granted							35,000
Number of options granted, exercise price							$ 2.24
Options vesting period							2 years
Six Employees [Member] | 2016 Equity Incentive Plan [Member]
Fair value of options											$ 41,825
Number of options granted											95,000
Options vesting period											3 years
Six Employees [Member] | 2016 Equity Incentive Plan [Member] | Minimum [Member]
Number of options granted, exercise price											$ 1.40
Six Employees [Member] | 2016 Equity Incentive Plan [Member] | Maximum [Member]
Number of options granted, exercise price											$ 1.84
Employee [Member] | 2016 Equity Incentive Plan [Member]
Fair value of options											$ 81,688
Number of options granted											100,000
Number of options granted, exercise price											$ 1.75
Options vesting period											1 year
Bridge Notes [Member]
Debt conversion description														Conversion would be based upon the price that is the lesser of: (i) $1.60 per share and (ii) the quotient obtained by dividing (x) the Outstanding Balance on the conversion date multiplied by 1.20 by (y) the actual price per share in the Qualified Financing. The notes and the warrants were further subject to a "most-favored nation" clause in the event the Company, prior to maturity of the notes, consummates a financing that is not a Qualified Financing. Upon completion of a Qualified Financing, in connection with the conversion of the Bridge Notes, the Company would also pay the Placement Agent up to 8% in cashless broker warrants with an exercise price of $3.00 and an expiry date of two years from the date of issuance.
Conversion price per share														$ 1.60
Debt converted into shares, value		$ 2,455,000
Debt converted into shares		1,823,020
Bridge Notes [Member] | Common Share Offering [Member]
Proceeds from issuance of common stock														$ 3,000,000
Warrant [Member]
Fair value of warrants														$ 3,183,614
Number of shares issued for exercise of warrants														252,798
Proceeds from exercise of warrants														$ 428,311
Warrant [Member] | Accredited Investors [Member] | Private Placement [Member]
Number of warrants issued														131,594
Warrant [Member] | Advisor and Consultant [Member]
Expected life											3 years
Warrant [Member] | Advisor and Consultant [Member] | Minimum [Member]
Risk free rate											2.13%
Stock price								$ 0.48			$ 0.48
Expected volatility											97.80%
Warrant [Member] | Advisor and Consultant [Member] | Maximum [Member]
Risk free rate											2.81%
Stock price								4.15			$ 4.15
Expected volatility											138.27%
Broker Warrants [Member]
Fair value of warrants														$ 385,635
Proceeds from exercise of warrants						$ 124,718
Cashless exercise of warrants														58,795
Number of warrants exercised						112,798								108,799
Broker Warrants [Member] | Minimum [Member]
Warrants exercise price per share						$ 1.04		0.78		$ 1.04	$ 0.78	$ 1.04
Broker Warrants [Member] | Maximum [Member]
Warrants exercise price per share						$ 1.49		3.00		1.49	$ 3.00	1.49
Broker Warrants [Member] | Accredited Investors [Member] | Private Placement [Member]
Number of warrants issued														21,055
Registered Offering [Member]
Number of shares issued														450,164
Proceeds from issuance of common stock														$ 2,520,561
Common Stock [Member]
Number of shares issuable											186,666
Common Stock One [Member]
Number of shares issuable											211,666
Consultant Warrants [Member]
Proceeds from exercise of warrants						$ 303,200
Number of warrants exercised						140,000
Consultant Warrants [Member] | Minimum [Member]
Warrants exercise price per share						$ 2.00		0.48		2.00	$ 0.48	2.00
Consultant Warrants [Member] | Maximum [Member]
Warrants exercise price per share						$ 2.58		$ 7.59		$ 2.58	$ 7.59	$ 2.58
Exchange Agreement [Member] | IMedical Innovations Inc [Member]
Common stock exchange description			1.197 shares of its common stock in exchange for each common share1.197 shares of its common stock in exchange for each common share
Number of shares issued			13,376,947
Exchange Agreement [Member] | IMedical Innovations Inc [Member] | 11% Secured Convertible Promissory Notes [Member]
Conversion description			The adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricity's next offering.
Exchange Agreement [Member] | IMedical Innovations Inc [Member] | Warrant [Member]
Common stock exchange description			1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1
Exchange ratio			1.197:1
Exchange Agreement [Member] | IMedical Innovations Inc [Member] | Advisor Warrant [Member]
Common stock exchange description			The terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1
Exchange ratio			1.197:1
Exchange Agreement [Member] | IMedical Innovations Inc [Member] | Options [Member]
Common stock exchange description			1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1
Exchange ratio			1.197:1
Exchange Agreement [Member] | Exchangeco [Member]
Common stock exchange description			1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held.								Shareholders holding 3,275,478 exchangeable shares with voting rights and other attributes corresponding to the Company's common stock (but with the additional right to cashlessly exchange on a one-for-one basis into common stock) retracted and exchanged their exchangeable shares for the corresponding number of shares of common stock.
Number of exchangeable shares issued			9,123,031
Pre-Exchange Agreement [Member] | 2015 Equity Incentive Plan [Member]
Number of shares issued for exercise of options																	2,832,500

[1] Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.

[2] Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.